Advances in the Understanding and Clinical Management of Mastocytosis and Clonal Mast Cell Activation Syndromes

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2016 Dec 3

PMID 27909577

Citations 5

Authors

David Gonzalez-de-Olano

Almudena Matito

Alberto Orfao

Luis Escribano

Affiliations

Soon will be listed here.

Abstract

Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities.

Citing Articles

Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach.

Zanelli M, Pizzi M, Sanguedolce F, Zizzo M, Palicelli A, Soriano A Cancers (Basel). 2021; 13(13).

PMID: 34282774 PMC: 8269078. DOI: 10.3390/cancers13133316.

Impact of Probiotic Bacteria on Respiratory Allergy Disorders.

Jakubczyk D, Gorska S Front Microbiol. 2021; 12:688137.

PMID: 34234762 PMC: 8256161. DOI: 10.3389/fmicb.2021.688137.

Clinical Utility of Rush Venom Immunotherapy: Current Status.

Gruzelle V, Mailhol C, Waters D, Guilleminault L J Asthma Allergy. 2020; 13:1-10.

PMID: 32021308 PMC: 6954838. DOI: 10.2147/JAA.S200917.

Insights in Anaphylaxis and Clonal Mast Cell Disorders.

Gonzalez-de-Olano D, Alvarez-Twose I Front Immunol. 2017; 8:792.

PMID: 28740494 PMC: 5502410. DOI: 10.3389/fimmu.2017.00792.

Systemic mastocytosis with V560G mutation presenting as recurrent episodes of vascular collapse: response to disodium cromoglycate and disease outcome.

Conde-Fernandes I, Sampaio R, Moreno F, Palla-Garcia J, Teixeira M, Freitas I Allergy Asthma Clin Immunol. 2017; 13:21.

PMID: 28439288 PMC: 5402055. DOI: 10.1186/s13223-017-0193-x.

References

Escribano L, Diaz-Agustin B, Lopez A, Nunez Lopez R, Garcia-Montero A, Almeida J . Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom. 2004; 58(1):1-8. DOI: 10.1002/cyto.b.10072. View

Matito A, Bartolome-Zavala B, Alvarez-Twose I, Sanchez-Matas I, Escribano L . IgE-mediated anaphylaxis to Hippobosca equina in a patient with systemic mastocytosis. Allergy. 2009; 65(8):1058-9. DOI: 10.1111/j.1398-9995.2009.02270.x. View

Kontou-Fili K, Filis C . Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy. 2009; 64(9):1384-5. DOI: 10.1111/j.1398-9995.2009.02045.x. View

ALEXANDER R . Disodium cromoglycate in the treatment of systemic mastocytosis involving only bone. Acta Haematol. 1985; 74(2):108-10. DOI: 10.1159/000206179. View

Lindskov R, Lange Wantzin G, Knudsen L, Soondergaard I . Urticaria pigmentosa treated with oral disodium cromoglycate. Dermatologica. 1984; 169(1):49-52. DOI: 10.1159/000249567. View

Douglass J, Carroll K, Voskamp A, Bourke P, Wei A, OHehir R . Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy. 2009; 65(7):926-7. DOI: 10.1111/j.1398-9995.2009.02259.x. View

Escribano L, Orfao A, Villarrubia J, Cervero C, Lopez A, Marcos M . Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998; 91(8):2731-6. View

Escribano L, Akin C, Castells M, Orfao A, Metcalfe D . Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol. 2002; 81(12):677-90. DOI: 10.1007/s00277-002-0575-z. View

Matito A, Morgado J, Alvarez-Twose I, Sanchez-Munoz L, Pedreira C, Jara-Acevedo M . Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One. 2013; 8(10):e76116. PMC: 3796517. DOI: 10.1371/journal.pone.0076116. View

10.

Metcalfe D . The treatment of mastocytosis: an overview. J Invest Dermatol. 1991; 96(3):55S-56S; discussion 56S-59S. View

11.

Sanchez-Munoz L, Morgado J, Alvarez-Twose I, Matito A, Garcia-Montero A, Teodosio C . Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol. 2015; 172(1):56-63. DOI: 10.1111/bjh.13789. View

12.

De Matteis G, Zanotti R, Colarossi S, de Benedittis C, Garcia-Montero A, Bonifacio M . The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis. Leuk Res. 2015; 39(3):273-8. DOI: 10.1016/j.leukres.2014.11.029. View

13.

Ting S . Ketotifen and systemic mastocytosis. J Allergy Clin Immunol. 1990; 85(4):818. DOI: 10.1016/0091-6749(90)90205-i. View

14.

Smith M, Orton P, Chu H, Weston W . Photochemotherapy of dominant, diffuse, cutaneous mastocytosis. Pediatr Dermatol. 1990; 7(4):251-5. DOI: 10.1111/j.1525-1470.1990.tb01020.x. View

15.

Lim A, Ostor A, Love S, Crisp A . Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis. 2005; 64(6):965-6. PMC: 1755523. DOI: 10.1136/ard.2004.029116. View

16.

Escribano L, Navalon R, Nunez R, Diaz Agustin B, Bravo P . Immunophenotypic analysis of human mast cells by flow cytometry. Curr Protoc Cytom. 2008; Chapter 6:Unit 6.6. DOI: 10.1002/0471142956.cy0606s12. View

17.

Rossini M, Zanotti R, Viapiana O, Tripi G, Orsolini G, Idolazzi L . Bone involvement and osteoporosis in mastocytosis. Immunol Allergy Clin North Am. 2014; 34(2):383-96. DOI: 10.1016/j.iac.2014.01.011. View

18.

Valent P, Akin C, Arock M, Brockow K, Butterfield J, Carter M . Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2011; 157(3):215-25. PMC: 3224511. DOI: 10.1159/000328760. View

19.

Gonzalez-de-Olano D, Alvarez-Twose I, Vega A, Orfao A, Escribano L . Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. Immunotherapy. 2011; 3(5):637-51. DOI: 10.2217/imt.11.44. View

20.

Garcia-Montero A, Jara-Acevedo M, Teodosio C, Sanchez M, Nunez R, Prados A . KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108(7):2366-72. DOI: 10.1182/blood-2006-04-015545. View